Abstract 830P
Background
To evaluate treatment efficacy for gastric extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma), histologic assessment via multiple gastric biopsies every 3 months constitutes the current gold standard. Currently, non-invasive diagnostic measures including PET-MRI to monitor therapy response in MALT lymphoma patients remain experimental for the time-being. While liquid biopsies isolating cell-free DNA (cfDNA) are used in other tumor entities for diagnostic and treatment monitoring measures, no data for gastric MALT-lymphoma have been published so far. Thus, we performed a pilot series to assess cfDNA in therapy-naïve gastric MALT-lymphoma patients.
Methods
For the isolation of cfDNA, blood from patients with MALT lymphoma was collected using PAXgene Blood ccfDNA tubes (Qiagen). cfDNA was isolated using the QIAamp Circulating Nucleic Acid Kit (Qiagen). DNA concentration was measured using fluorescence quantification (Qubit, Thermo Fisher). Quantitative data were compared to 68-Ga-Pentixafor-PET/MRI performed within 4 weeks assessing active lymphoma volumes. Clinical parameters were obtained by chart review.
Results
A total of 15 patients (4 males, 11 females) with MALT lymphoma at a median age of 64 years (range: 44-79) were included in this study. cfDNA could be isolated in all patients with a median concentration of 5.4ng/ml plasma (range: 3.6-12.4ng/ml). Compared to a healthy control cohort (n=5), cfDNA levels were significantly increased in MALT lymphoma patients (3.8ng/ml vs. 5.9ng/ml, p=0.025). In 12/15 patients, a follow-up blood draw could be obtained after a median 3.3 months (range 0.9-7.0 months). cfDNA levels remained stable during that time period with a mean concentration of 5.7ng/ml at baseline and 6.3ng/ml at follow-up (p>0.05). Correlation between metabolically active tumor volume and cfDNA concentration will be reported as soon as radiologic reclassification is completed.
Conclusions
cfDNA may be used as a non-invasive biomarker for disease monitoring in patients with MALT lymphoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged.
Disclosure
B. Kiesewetter-Wiederkehr: Financial Interests, Personal, Invited Speaker: Ipsen, Novartis, MSD, Advanced Accelerator Applications (AAA), Boehringer Ingelheim, Eli Lilly; Financial Interests, Personal, Advisory Board: Ipsen, Roche, Eli Lilly, MSD; Non-Financial Interests, Project Lead, Young Hematologist and Oncologists Group Austria (YHOGA): Austrian Society for Hematology and Medical Oncology (OeGHO). A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer-Ingelheim, Bristol Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GSK, AbbVie; Financial Interests, Institutional, Coordinating PI: PharmaMar; Non-Financial Interests, Leadership Role, Brain Tumor Group Chair (current): EORTC; Non-Financial Interests, Leadership Role, EANO Past-President (current): EANO; Non-Financial Interests, Other, Member Multi-Site Guideline Advisory Group: ASCO. M. Raderer: Financial Interests, Personal, Other, Honoraria: BeiGene, Celgene, Eli Lilly, Gilead, Galapagos, Ipsen, Novartis, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18